The FIBTEM paradox: Do coronary artery bypass grafting patients with high baseline FIBTEM clot firmness need more allogeneic blood transfusion?
Seung ChoiMichael A MazzeffiReney HendersonSamhati MondalYoshihisa MoritaSeema DeshpandeKenichi A TanakaPublished in: Transfusion (2022)
The high FIBTEM group frequently presented with anemia and comorbidities, and received more RBCs but not non-RBC products. Postoperative blood loss was less with high FIBTEM, and after adjustments, it conferred protection against any transfusion.